The Portable Neuromodulation Stimulator (PoNS) Device for MS-associated Gait Problems Now Available in US - Multiple Sclerosis (MS) Information, and resources

By Lindsey Shapiro PhD on 04/29/2022

The portable neuromodulation stimulator (PoNS) device, which improves walking abilities in people with multiple sclerosis (MS), is now available commercially in the U.S. for patients ages 22 and older who have a prescription from their healthcare provider.

The device was approved last year by the U.S. Food and Drug Administration (FDA), which stipulated that it could be used for the short-term treatment of gait problems due to mild or moderate MS in conjunction with supervised physical therapy.

The device may help MS patients in the U.S. see improvements in mobility, disability, and quality of life, according to its developer, Helius Medical Technologies.

“Approximately 40 percent of individuals with MS will need walking assistance within 15 years of the onset of the disease. PoNS therapy provides a unique opportunity for these patients to improve gait functionality and mobility,” Antonella Favit-Van Pelt, MD, PhD, Helius’ chief medical officer, said in a press release.

Walking difficulties are among the most common symptoms of MS. Often, walking can be improved with physical therapy, stretching, and assistive walking devices, sometimes in combination with medication.

PoNS is a noninvasive portable device consisting of a mouthpiece that’s connected via a cord to a controller worn around the neck.

When placed on the tongue, the mouthpiece delivers a light electrical stimulation to two nerves, called cranial nerves, which send electrical signals to the brain. These electrical signals promote neuroplasticity, a process wherein the brain adapts and rewires in response to new experiences. This is thought to promote the strength of brain circuits involved in movement and enhance the benefits of physical therapy in people with mild-to-moderate MS.

“We believe that we are unlocking the full potential of neuromodulation and neuroplasticity to help MS patients walk more steadily and safely,” Favit-Van Pelt said.